Aaron Rossi
Dr. Aaron Rossi finished his undergraduate work at Elmhurst College in 2006 before enrolling in the University of Sint Eustatius School of Medicine to continue his medical education in 2012. Dr. Rossi identified a particular interest and aptitude for successfully managing private medical practices while in medical school. Following graduation, he began a journey through numerous healthcare industry professions, improving his knowledge and creating a broad range of skills.
Dr. Rossi developed a successful approach to managing private practices because he was passionate about helping independent doctors navigate the constantly changing healthcare environment. The practice's income doubled in less than four years as he turned a struggling single-provider practice in Central Illinois into a profitable multi-specialty group. He can better understand the everyday difficulties experienced by private practitioners because of his commitment to maintaining contact with doctors who are directly involved in patient care. Dr. Rossi, who has a disruptive personality, works to empower physicians and uphold their autonomy.
Dr. Rossi purchased PAL Health Technologies in March 2018, a laboratory with a four-decade history that fabricates prescription-tailored foot and ankle orthotics. He founded Reditus Laboratories, LLC in June 2019, just 15 months afterward. The lab started with a small staff of eight people and initially concentrated on histology and Dermatopathology. But in December 2019, Dr. Rossi added PCR testing for infectious disorders, enhancing the laboratory's capabilities. This was the first step towards a quick and reliable diagnosis of infections in soft tissue and wounds, made possible by purchasing an RT-PCR (real-time reverse transcriptase polymerase chain reaction) system.
When the SARS-CoV-2 (COVID-19) epidemic hit in March 2020, Dr. Aaron Rossi was forced to act quickly in his commercial ventures. He briefly changed PAL's manufacturing to make face shields for American hospitals and first responders. Meanwhile, he led the national expansion of PCR COVID-19 testing through Reditus Laboratories. Distinguished collaborations were established with groups, including Smithfield Foods, Illinois Department of Public Health, The Washington Ballet, United States Customs, Border Patrol, and several hospitals and educational institutions. Reditus Laboratories performed roughly five million COVID RT-PCR tests over two years.
The FDA EUA SARS-CoV-2 molecular test used by Reditus Laboratories presently uses extraction and RT-PCR techniques similar to those used by federal and state public health laboratories. These techniques may identify as little as 10 SARS-CoV-2 genomes with clinical samples, demonstrating their great analytical sensitivity and specificity. By using real-time reverse transcriptase polymerase chain reaction to detect viral nucleic acid in extracted clinical samples from the upper respiratory tract, nasopharynx, anterior nares, and bronchoalveolar lavages, the laboratory adheres to the gold standard of SARS-CoV-2 testing. Protein denaturants and chaotropic salts are applied to nasopharyngeal (NP), oropharyngeal (OP), and bronchoalveolar lavage (BAL) tissues to extract, purify, and concentrate viral nucleic acids while removing any inhibitory components that can reduce test sensitivity.
